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ABSTRACT 
HIV-infected women are at increased risk of cervical intra-epithelial neoplasia (CIN) and 
invasive cervical cancer (ICC), but it has been difficult to disentangle the influences of 
heavy exposure to HPV infection, inadequate screening, and immunodeficiency. A case-
control study including 364 CIN2/3 and 20 ICC cases matched to 1,147 controls was 
nested in the Swiss HIV Cohort Study (1985-2013). CIN2/3 risk was significantly 
associated with low CD4+ cell counts, whether measured as nadir (odds ratio (OR) per 
100-cell/µL decrease=1.15, 95% CI: 1.08, 1.22), or at CIN2/3 diagnosis (1.10, 95% CI: 
1.04, 1.16). An association was evident even for nadir CD4+ 200-349 versus ≥350 cells/µL 
(OR=1.57, 95% CI: 1.09, 2.25). After adjustment for nadir CD4+, a protective effect of >2-
year cART use was seen against CIN2/3 (OR versus never cART use=0.64, 95% CI: 0.42, 
0.98). Despite low study power, similar associations were seen for ICC, notably with nadir 
CD4+ (OR for 50 versus >350 cells/µL= 11.10, 95% CI: 1.24, 100). HPV16-L1 antibodies 
were significantly associated with CIN2/3, but HPV16-E6 antibodies were nearly 
exclusively detected in ICC. In conclusion, worsening immunodeficiency, even at only 
moderately decreased CD4+ cell counts (200-349 CD4+ cells/µL), is a significant risk 
factor for CIN2/3 and cervical cancer.  
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INTRODUCTION 
There is a substantial excess of invasive cervical cancer (ICC) among women infected 
with HIV (WHIV).1 This excess has tended to be largest in settings where WHIV have 
access to combined antiretroviral therapy (cART), but are not well reached by cervical 
screening.2-4 Studies have also shown a consistent excess of cervical intraepithelial 
neoplasia grade 2/3 (CIN2/3) in WHIV.5,6 
Sexual behaviors that favor acquisition of HIV are the same that favor the acquisition 
of high-risk human papillomavirus (HPV) types, which leads to a higher prevalence of HPV 
in WHIV.7 In addition, however, HIV-related immunodeficiency is known to unfavorably 
influence HPV natural history. CD4+ cell count is negatively associated with the 
prevalence,8-11 persistence,12 and cumulative incidence13 of HPV infection, as well as with 
cytological abnormalities11 and CIN2/36,14,15 among WHIV.  
The effects of HIV-related immunodeficiency on ICC have been more difficult to 
establish. Firstly, ICC has been classified as an acquired immunodeficiency syndrome 
(AIDS)-defining cancer since 1993, which created problems for early linkage studies 
between people with AIDS and cancer registries. Many prevalent cervical cancers 
diagnosed at AIDS onset had to be excluded from estimations of relative risk.16 Secondly, 
screening can substantially curb the ICC burden.17 Only in recent years are large studies 
of WHIV revealing that CD4+ cell count is indeed negatively related to ICC risk.18-20  
The dose response relationship between the level of immunodeficiency and the risk 
of CIN2/3 and ICC remains unclear, however, as does the effect of cART-induced 
improvements in immunity on the evolution of cervical neoplasia. Thus, we undertook a 
case-control study nested within the Swiss HIV Cohort Study (SHCS), a nationwide study 
of HIV-positive persons, to characterize the influence of immunodeficiency and cART use 
on the development of CIN2/3 and ICC among WHIV. 
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MATERIAL AND METHODS 
The Swiss HIV Cohort Study 
The SHCS is nationwide prospective cohort that has been enrolling HIV-infected persons 
aged 16 years or older since 1988 from all five Swiss University hospitals (Basel, Bern, 
Geneva, Lausanne and Zurich), and two cantonal hospitals (St Gallen and Ticino).21 Since 
1995, interested private physicians have also been enrolling patients. Twenty-eight 
percent of participants in the SHCS are women. The database used for the current study 
included a total of 5,150 female SHCS participants contributing approximately 35,000 
person years of active follow-up until October 2013. Detailed information on all AIDS-
related diseases, CD4+ cell count and HIV-related treatments are collected at enrollment,  
and at each six-month follow-up visit. Questions on smoking history were asked to SHCS  
participants at all enrollment and follow-up visits after April 2000.   
History of Papanicolaou (Pap) smear was self-reported by SHCS participants at all  
enrollment and follow-up SHCS visits after April 2000. Pap smear history was censored at  
the SHCS visit preceding the reference date (see definition below), which should exclude  
the smear that led to diagnosis of CIN2/3 or ICC.   
Written informed consent was obtained from all SHCS participants. The present  
study was approved by the local ethical committees of the seven SHCS sites and of the  
International Agency for Research on Cancer.  
  
Ascertainment of incident cases  
Cases of CIN2/3 and of ICC are routinely recorded in the SHCS. Additional cases  
were identified through record linkage with eight cantonal cancer registries.22,23 Prevalent  
CIN2/3 and ICC cases were defined as women diagnosed before, or within one month of  
enrolment into the SHCS and were excluded from analyses.   
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Selection of controls 
Three control women never diagnosed with CIN2/3 or ICC were matched to each 
CIN2/3 or ICC case using incidence density sampling.24 Controls had at least the same 
length of follow-up as the matched case, and could serve as controls for only one case. 
Matching criteria were: 1) SHCS centre; 2) HIV-transmission category (injecting drug users 
[IDU], heterosexual/other); 3) age at enrollment in SHCS (as close as possible, up to a 
maximum of nine years difference); 4) calendar year of enrollment in SHCS (as close as 
possible, up to a maximum of nine years difference). For each case a list of possible 
controls was drawn up and three controls were selected at random. 
  
Definitions  
For each case-control pair, the reference date was defined as the date corresponding  
to the same length of follow-up as the matched case had at the time of the diagnosis of  
CIN2/3 or ICC (thus cases and controls were also matched for age and year of reference  
date). The nadir CD4+ cell count was defined as the lowest ever reported CD4+ cell count  
prior to the reference date.  
cART use was defined as a combination of at least three antiretroviral drugs,  
including a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor or three  
nucleosides, including abacavir. Only persons who had used cART for more than one  
month prior to the reference date were classified as ever users, and cART users were  
additionally stratified by duration of use from date of cART initiation to reference date (≤2  
years versus >2 years). This duration may include periods of interruptions, but these occur  
in only a small fraction of SHCS participants on cART (5-10%).25  
History of AIDS was defined as a history of any AIDS-defining illness prior to the  
reference date. Of note, for ICC and corresponding controls, AIDS-defining events were  
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counted only if diagnosed at least 3 months before the reference date, to avoid that ICC 
itself was the first AIDS-defining illness.  
We considered CIN2/3 and ICC to be different biological entities and chose not to 
combine in any analyses. 
 
HPV serology 
For a sub-set of CIN2/3 and ICC cases with available serum samples (79 and 13, 
respectively), as well as 248 corresponding controls, HPV antibodies were tested in serum 
samples taken closest in time prior to the reference date. HPV antibodies were tested at 
the German Cancer Research Center (DKFZ) in Heidelberg, Germany, using multiplex 
bead-based technology (xMAP, Luminex Corporation, Austin, Texas)26 including antigens 
for L1, and E6 proteins of HPV16. Antigens were categorized as antibody positive or 
negative by applying previously defined antigen-specific cut-off values.27 
 
Statistical Analysis 
Odds ratios (OR) and corresponding 95% confidence intervals (CI) for possible risk 
factors were computed separately for CIN2/3 and ICC by univariate conditional logistic 
regression conditioned on matching variables. For CD4+ cell count measures, OR were 
also calculated per 100cells/µl decrease considering CD4+ cell count as a continuous 
variable. The OR for cART use adjusted for nadir CD4+ cell count was additionally 
computed. In analyses stratified by ever versus never cART use, however, OR for nadir 
CD4+ cell count were computed by unconditional logistic regression with adjustment for 
matching variables (SHCS centre; HIV-transmission category; age at enrollment; year at 
enrollment), due to the need to break case:control pairs (cART use was not a matching 
criteria). Missing data were considered as a separate category in the above models. For 
smoking and Pap smear history that were unavailable prior to April 2000 and April 2001 
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respectively, conditioning on year at reference date meant that most missing data 
clustered in the same case:control pairs which were effectively dropped from the estimates 
for these two variables). Chi-square for trend was calculated for the categories listed in the 
tables. P values of all statistical tests were two-sided. 
Median CD4+ cell counts were calculated separately for never and ever cART users 
in yearly periods prior to the reference date, restricted to cases and controls who (1) were 
under active follow-up and (2) had a valid CD4+ cell count, in each yearly period. If more 
than one measurement was available during any one time period, that closest to the 
reference date was used. Matching was not retained in the presentation of median CD4+ 
cell counts. 
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RESULTS 
A total of 508 CIN2/3 and 40 ICC cases were identified in SHCS participants, of whom 437 
and 32 were identified from the SHCS database, and 71 and 8 additional cases were 
identified through record linkage with eight population-based Swiss Cantonal Cancer 
Registries.22,23 One hundred and forty CIN2/3 and 16 ICC occurring before (or within one 
month of) SHCS enrollment, as well as four CIN2/3 and four ICC diagnosed more than six 
months after the last SHCS follow-up date, were excluded, leaving 364 and 20 eligible 
incident cases occurring during active SHCS follow-up, respectively.  
Table 1 shows the distribution of the CIN2/3 and ICC cases, as well as their 
respective controls, by matching variables. For five CIN2/3 cases, only two valid controls 
were available. A majority of both CIN2/3 and ICC cases were diagnosed after the 
introduction of cART in 1996 (72% and 65% respectively), and were under active follow-up 
in the SHCS for less than five years prior to diagnosis (66% and 60%, respectively). 
However, ICC cases (mean age 34.3 years) were older than CIN2/3 cases(29.7).  
There were no significant associations with history of Pap smear, neither for CIN2/3 
nor ICC, but this information was available only for case:control pairs whose reference 
date was after April 2001 (the date at which this information started to be collected in the 
SHCS). Nevertheless, findings did suggest frequent lack of screening among ICC cases 
(37.5%) (Table 2). There was no association of smoking history with CIN2/3 and, although 
75% of ICC cases were current or former smokers compared to 51% of controls, this 
difference did not reach statistical significance. Likewise, no associations with a history of 
AIDS were observed for either CIN2/3 or ICC (Table 2).  
Associations of CIN2/3 and ICC with various markers of immunodeficiency are also 
shown in Table 2. CIN2/3 (OR per 100 cell/µL decrease = 1.10, 95% CI: 1.04, 1.16) and 
ICC (1.16, 95% CI: 0.89, 1.51) were similarly associated with low CD4+ cell count at 
reference date, although the ICC association did not reach statistical significance. CIN2/3 
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was also significantly associated with CD4+/CD8+ ratio (OR for <0.25 versus >0.50 = 1.67, 
95% CI: 1.19, 2.35). No significant trend in association with CIN2/3 or ICC was observed 
for HIV viral load (Table 2), or CD8+ cell count (data not shown). CIN2/3 was significantly 
associated with a low nadir CD4+ cell count (OR per 100 cells/µL decrease = 1.15, 95% 
CI: 1.08, 1.22), even at moderate levels of immunosuppression (OR for 200-349 versus 
≥350 cells/µL = 1.57, 95% CI: 1.09, 2.25). For ICC, an equally strong trend as for CIN2/3 
was found (OR per 100 cells/µL decrease = 1.19, 95% CI: 0.88, 1.60), but only the 
comparison of nadir CD4+ cell count of <50 versus ≥500 cells/µL reached statistical 
significance (OR=11.10, 95% CI: 1.24, 100). 
About half of CIN2/3 and ICC cases had started cART before the reference date 
(Table 3), but there were no significant differences in cART use between cases and 
controls for either disease. Upon stratification by duration of cART use, however, women 
with ≤2 years use showed elevated CIN2/3 risks compared to never users, whilst those 
with >2 years use showed non-significantly reduced risks. After additional adjustment for 
nadir CD4+ cell count, the OR for >2-years cART use was associated with a significant 
reduction in CIN2/3 risk (OR=0.64, 95% CI: 0.42, 0.98). A similar association, albeit non-
significant, was seen for ICC risk (e.g. OR for ≥2years versus never=0.34, 95% CI: 0.05, 
2.26) (Table 3). 
Table 4 shows associations of nadir CD4+ cell count with CIN2/3 and ICC, stratified 
by cART use (never/ever). Nadir CD4+ cell count was significantly associated with CIN2/3 
risk both among ever users (OR per 100 cell/µL decrease = 1.12, 95% CI: 1.03, 1.21) and 
never users (1.17, 95% CI: 1.05, 1.30). Nadir CD4+ cell count was strongly associated 
with ICC risk in never users (OR for <50 versus ≥350 cells/µL= 12.90, 95% CI: 0.38, 436, 
P for trend=0.004), but the corresponding associations did not reach statistical significance 
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in ever users (OR for <50 versus ≥350 cells/µL= 6.41, 95% CI: 0.43, 95.1, P for 
trend=0.26).  
Figure 1 shows median CD4+ cell counts in yearly periods prior to the reference date 
in CIN2/3 cases and controls, separately for never and ever cART users. As expected, 
mean CD4+ cell counts among both cases and controls declined over time among never 
cART users (Figure 1A) but were stable in ever cART users (Figure 1B). Median CD4+ cell 
count was lower in cases compared to that in controls at most time points prior to the 
reference date, and the size of this difference did not appear to vary by time period, neither 
for never or ever users. Indeed, the association between CIN2/3 risk and more historical 
measures of CD4+ count was similar to that for CD4+ cell count at reference date (e.g.  
matched OR per 100 cells/µL decrease for CD4+ cell count 3-4 years prior to reference  
date = 1.15, 95% CI: 1.05-1.25, data not shown). Numbers were too few to allow a similar  
analysis for ICC.  
Seropositivity for anti-HPV16E6 was found in 2 out of 13 ICC cases (15%) compared  
to 0 out of 37 controls. Three out of 79 CIN2/3 cases and 6 out of 211 corresponding  
controls were seropositive for anti-HPV16E6. Seroprevalence of anti-HPV16L1 was  
significantly higher in CIN2/3 cases (40%) than controls (26%) (OR = 1.93, 95% CI: 1.09,  
3.40) (Figure 2).   
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DISCUSSION 
Our carefully matched case-control study within the SHCS was able to confirm the 
role of immunodeficiency in the aetiology of CIN2/314,15 and ICC18-20 among WHIV. 
Furthermore, we showed that increases in CIN2/3 and ICC risk are already evident even at 
moderate levels of immunosuppression (200-349 cells/µL), similar to our recent findings in 
the SHCS for anal cancer, which is also HPV-related.28 Low CD4+ cell counts at diagnosis 
were significantly associated with risk of CIN2/3, but nadir CD4+ cell count appeared a 
more discriminant CD4+ measure of both CIN2/3 and ICC.  
We were able to demonstrate a protective effect of cART use on the risk of CIN2/3, 
but exclusively if the use had lasted 2 years or more. Whereas early studies failed to show 
a significant effect of cART use on HPV-related outcomes, others have since reported 
significant decreases in prevalence of HPV infection,15,29 incidence of cytological lesions,30 
or carcinoma in situ/ICC4 in medium/long-term users. In our study, the protective effect of 
cART use on CIN2/3 was strengthened by adjusting for nadir CD4+ cell count, which 
partially adjusts for the negative confounding of CD4+ cell count by indication to treat. 
Indeed, cART tends to be initiated only when CD4+ cell count falls below a certain level, 
so that non-cART users had higher average nadir CD4+ cell counts than cART users. In 
our present study, mean nadir CD4+ cell count in cART users was 163 in CIN2/3 and 207 
in corresponding controls, versus 293 and 363, respectively among non-cART users. 
Previous findings of lack of influence of cART may thus be due to lack of accounting for 
duration of treatment and CD4+ cell count at cART initiation. 
As more than half of cases and controls had never used cART at the reference date, 
we were able to show the effect of nadir CD4+ cell counts on CIN2/3 both in ever and 
never users of cART. Two previous studies on this topic showed that CD4+ cell counts at 
diagnosis were significantly associated with CIN2/3 risk, but in non-cART users only.14,15 
These findings suggest that cART use can only partially eliminate the negative influence of 
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a low nadir on CIN2/3, which differs from other AIDS-defining malignancies like 
immunoblastic non-Hodgkin lymphoma31 and Kaposi sarcoma32 in which cART can rapidly 
lower cancer risk. Hence the benefits of cART on ICC may be limited by the non-
reversibility of certain pre-invasive stages. 
Cervical cancer screening is a pre-requisite for diagnosis of CIN2/3, and its treatment 
has undoubtedly curbed incidence rates of ICC in the SHCS. Even in the SHCS, however, 
screening has been sub-optimal with 20-30% of WHIV in the control groups reporting no 
history of Pap smear screening. Indeed, among the eight ICC cases diagnosed after 2001 
with information on past screening, five had no history of Pap smear. Two ICC cases 
reported abnormal Pap smears and only one case a normal Pap smear in the two years 
prior to ICC diagnosis. Thus the excess risk of ICC seen during the pre-cART period in the 
SHCS in comparison to the general population22 is likely to be a combination of 
immunodeficiency and inadequate screening and/or treatment of precancerous lesions.  
Our limited data on anti-HPV16 L1 seroprevalence demonstrates the high burden of 
HPV in SHCS women. Thirty percent of women in the control group were seropositive for 
anti-HPV16 L1, which compares to only 10% among mixed-sex controls from a large 
European-wide population-based study using the same serological assay.33 Furthermore, 
whilst anti-HPV16 L1 is considered the best marker of cumulative exposure to HPV16 
infection, the reported seroprevalence is certainly an under-estimate as a substantial 
fraction of HPV infections are known not to elicit L1 seroconversion.34  
Antibodies to HPV16 E6 were seen in ICC, but were almost absent, not only in 
controls, but also in CIN2/3, confirming them as a marker specific to late stages of HPV 
malignant transformation in the anogenital tract.33 Nevertheless, only 15% of ICC cases 
were seropositive for antibodies against HPV16 E6, which compares to 32% seen in 
serum samples taken close in time to ICC in the HIV-negative population.35  
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An association, albeit non-significant, between smoking and ICC risk in WHIV is 
consistent with the sexual behavior-adjusted findings from a large pooled analysis of ICC 
in HIV-uninfected women36 and with the significant association seen for anal cancer in the 
SHCS28 and CIN2/3 in WHIV in the U.S.6  
The SHCS has many strengths, including the duration (predating the introduction of 
cART) and regularity of follow-up and medication, as well as the comprehensiveness of 
clinical and laboratory information. Approximately half of all persons with HIV in 
Switzerland have been enrolled in the SHCS, and females and non-cART users are well 
represented. An additional strength was the supplement of CIN2/3 and ICC diagnoses 
through linkage with cancer registries. However, the SHCS was not designed to evaluate 
the natural history of HPV infection and related disease, with gynecological consultations 
occurring largely outside the framework of the study. Hence, Pap smear history was based 
on self-report, being added in 2001 only, without any information on cytological diagnoses, 
and the SHCS does not collect the ideal type of sample for HPV testing (i.e. cervical cells 
and/or biopsies). This meant that it was not possible to review histological diagnoses, in 
order to confirm ICC, or to separate CIN 2 from the truer cancer precursor, CIN3.37 
Furthermore, the completeness of recording of CIN2/3 in the SHCS is known to differ over 
time and between cantons. This is one reason that a nested case:control design with 
careful matching is probably more appropriate than an incidence rate approach. Although 
ICC cases were few and gave us limited statistical power to achieve significant 
associations, previous data are very scant. Indeed, the historically sub-optimal level of 
cervical screening and treatment in the SHCS meant that the observed rate of ICC was 
higher than in well-screened cohort studies of WHIV.6 
In conclusion, our data suggest that worsening immunodeficiency, even at only 
moderately decreased CD4+ cell counts (200-349 CD4+ cells/µL), is a significant risk 
factor for CIN2/3 and cervical cancer. Thus, the earliness at which HIV infection is 
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detected and cART is subsequently initiated is, in combination with HPV vaccination and 
cervical screening, key to the prevention of cervical cancer in WHIV. 
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TABLE LEGENDS 
 
Table 1. Distribution of 364 Cervical Intra-epithelial Neoplasia 2/3 Cases, 20 Invasive 
Cervical Cancer Cases and 1,147 Control Subjects According to Matching Variables. The 
Swiss HIV Cohort Study, 1985-2013. 
 
Table 2. Odds Ratios for Cervical Intra-epithelial Neoplasia 2/3 and Invasive Cervical 
Cancer by Selected Characteristics at Reference Datea. The Swiss HIV Cohort Study, 
1985-2013. 
 
Table 3. Odds Ratios for Cervical Intra-epithelial Neoplasia 2/3 and Invasive Cervical 
Cancer by cART Use Before and After Adjustment for Nadir CD4 Cell Count. The Swiss 
HIV Cohort Study, 1985-2013. 
 
Table 4. Odds Ratios for Cervical Intra-epithelial Neoplasia 2/3 and Invasive Cervical 
Cancer by Nadir CD4+ Count, Separately Among never and ever cART Users. The Swiss 
HIV Cohort Study, 1985-2013. 
 
 
 
Page 22 of 33
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
 23 
 
FIGURE LEGENDS 
 
Figure 1. Box plots of CD4+ cell counts at yearly intervals prior to reference date, among 
cervical intra-epithelial neoplasia 2/3 and controls, stratified by A) never cART users and 
B) ever cART users. The Swiss HIV Cohort Study, 1985-2013. 
Abbreviations: CIN2/3 = cervical intra-epithelial grade 2/3; cART = combined antiretroviral 
therapy. 
A) Never cART users 
B) Ever cART users 
 
Figure 2. Seropositivity for HPV16 antibodies among cervical intra-epithelial neoplasia 
2/3, invasive cervical cancer and corresponding controls. The Swiss HIV Cohort Study, 
1985-2013. 
*Significantly different from corresponding controls in conditional logistic regression 
model. 
Abbreviations: HPV = human papillomavirus; CIN2/3 = cervical intra-epithelial grade 2/3; 
ICC = invasive cervical cancer. 
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Table 1. Distribution of 364 Cervical Intra-epithelial Neoplasia 2/3 Cases, 20 Invasive Cervical Cancer Cases 
and 1,147 Control Subjects According to Matching Variables. The Swiss HIV Cohort Study, 1985-2013. 
 CIN2/3 ICC 
 Cases Controls Cases Controls 
 N (%) N (%) N (%) N (%) 
         
Overall 364  1087  20  60  
         
Center         
   Basel 25 (6.9) 75 (6.9) 2 (10.0) 6 (10.0) 
   Bern 81 (22.3) 241 (22.2) 3 (15.0) 9 (15.0) 
   Geneva 54 (14.8) 162 (14.9) 1 (5.0) 3 (5.0) 
   St Gallen 45 (12.4) 134 (12.3) - - - - 
   Ticino 22 (6.0) 64 (5.9) - - - - 
   Vaud 44 (12.1) 132 (12.1) 5 (25.0) 15 (25.0) 
   Zurich 93 (25.5) 279 (25.7) 9 (45.0) 27 (45.0) 
         
HIV-transmission category       
   IDU 139 (38.2) 413 (38.0) 9 (45.0) 27 (45.0) 
   Het/Other 225 (61.8) 674 (62.0) 11 (55.0) 33 (55.0) 
         
Age at reference date (years)a       
   <30 91 (25.0) 268 (24.7) 3 (15.0) 10 (16.7) 
   30-34 119 (32.7) 328 (30.2) 6 (30.0) 13 (21.7) 
   35-39 87 (23.9) 276 (25.4) 2 (10.0) 16 (26.7) 
   ≥40 67 (18.4) 215 (19.8) 9 (45.0) 21 (35.0) 
         
Calendar period at reference datea      
   1985-1992 22 (6.0) 86 (7.9) 3 (15.0) 11 (18.3) 
   1993-1996 80 (22.0) 201 (18.5) 4 (20.0) 5 (8.3) 
   1997-2001 120 (33.0) 326 (30.0) 4 (20.0) 17 (28.3) 
   2002-2006 76 (20.9) 293 (27.0) 5 (25.0) 22 (36.7) 
   2007-2013 66 (18.1) 181 (16.7) 4 (20.0) 5 (8.3) 
         
Duration of follow-up before reference date (years)a    
   0-1 146 (40.1) 437 (40.2) 8 (40.0) 24 (40.0) 
   2-4 93 (25.5) 280 (25.8) 4 (20.0) 12 (20.0) 
   5-9 88 (24.2) 266 (24.5) 2 (10.0) 6 (10.0) 
   ≥10 37 (10.2) 104 (9.6) 6 (30.0) 18 (30.0) 
         
Abbreviations: CIN, cervical intra-epithelial neoplasia; Het, heterosexual; ICC, invasive cervical 
cancer; IDU, intravenous drug users. 
 areference date for cases = date of diagnosis of ICC or CIN2/3, and for controls = date after a 
similar length of follow-up in the Swiss HIV Cohort Study as the corresponding matched case. 
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Table 2. Odds Ratios for Cervical Intra-epithelial Neoplasia 2/3 and Invasive Cervical Cancer by Selected 
Characteristics at Reference Datea. The Swiss HIV Cohort Study, 1985-2013. 
 CIN2/3 ICC 
 Cases  Controls ORb 
(95% CI) 
Cases  Controls  ORb (95% CI) 
 N (%) N (%) N % N %  
Overall 364  1087   20  60   
           
History of Pap smear         
No 40 (29.2) 129 (28.1) 1 3 (37.5) 5 (20.8) 1 
Yes 97 (70.8) 330 (71.9) 0.90 (0.57, 1.41) 5 (62.5) 19 (79.2) 0.39 (0.06, 2.45) 
Unknownc 227  628   12  36   
        
Smoking Status        
Never 89 (43.4) 289 (45.6) 1 3 (25.0) 18 (48.6) 1 
Former 17 (8.3) 59 (9.3) 0.93 (0.51, 1.70) 
1.13 (0.78-1.64) 
3 (25.0) 6 (16.2) 
} 3.73 (0.75, 18.6) Current 99 (48.3) 286 (45.1) 1.13 (0.78, 1.64) 6 (50.0) 13 (35.1) 
Unknownd 159  453   8  23   
           
History of AIDSe          
No 280 (76.9) 851 (78.3) 1 14 (70.0) 45 (75.0) 1 
Yes 84 (23.1) 236 (21.7) 1.08 (0.81, 1.45) 6 (30.0) 15 (25.0) 1.36 (0.39, 4.69) 
Unknown 227  628   12  36   
           
CD4+ cell count, cells/µL       
≥500 93 (27.4) 350 (35.7) 0.89 (0.62, 1.26) 3 (17.6) 20 (37.0) 0.95 (0.14, 6.60) 
350-499 70 (20.6) 238 (24.3) 1 2 (11.8) 10 (18.5) 1 
200-349 87 (25.7) 202 (20.6) 1.51 (1.04, 2.18) 8 (47.1) 15 (27.8) 3.49 (0.58, 21.1) 
<200 89 (26.3) 191 (19.5) 1.72 (1.16, 2.54) 4 (23.5) 9 (16.7) 3.04 (0.38, 24.3) 
Unknown 25  106   3  6   
χ
2 trend (P)     < 0.001     0.062 
Per 100 µL decrease 1.10 (1.04, 1.16)     1.16 (0.89, 1.51) 
       
CD4+/CD8+ ratio        
>0.50 140 (41.5) 502 (51.4) 1 6 (35.3) 23 (43.4) 1 
0.25-0.49 111 (32.9) 279 (28.6) 1.47 (1.09, 1.97) 
1.67 (1.19, 2.35) 
6 (35.3) 23 (43.4) } 1.38 (0.46, 4.16) 
<0.25 86 (25.5) 195 (20.0) 5 (29.4) 7 (13.2) 
Unknown 27  111   3  7   
χ
2 trend (P)   < 0.001      
       
HIV Viral load, copies/mL       
<500 175 (64.8) 472 (59.3) 1 8 (66.7) 22 (51.2) 1 
500-9,999 37 (13.7) 168 (21.1) 0.59 (0.39, 0.88) 
1.00 (0.70, 1.44) 
1 (8.33) 9 (20.9) } 0.53 (0.12, 2.33) ≥10,000  58 (21.5) 156 (19.6) 3 (25.0) 12 (27.9) 
Unknown 94  291   8  17   
χ
2 trend (P)     0.26      
           
Nadir CD4+ cell count, cells/µL        
≥350 68 (18.8) 323 (29.9) 1 2 (10.0) 16 (27.1) 1 
200-349 88 (24.4) 280 (25.9) 1.57 (1.09, 2.25) 4 (20.0) 15 (25.4) 2.94 (0.44, 19.9) 
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50-199 135 (37.4) 314 (29.0) 2.20 (1.55, 3.11) 9 (45.0) 21 (35.6) 4.45 (0.81, 24.4) 
<50 70 (19.4) 165 (15.2) 2.20 (1.47, 3.30) 5 (25.0) 7 (11.9) 11.10 (1.24, 100) 
Unknown 3  5   0  1   
χ
2 trend (P)     < 0.001     0.019 
Per 100 µL decrease   1.15 (1.08, 1.22)     1.19 (0.88, 1.60) 
           
Abbreviations: CI, confidence interval; CIN, cervical intra-epithelial neoplasia; ICC, invasive cervical cancer; OR, 
odds ratio.   
areference date for cases = date of diagnosis of ICC / CIN2/3, and for controls = date after a similar length of follow-
up in the SHCS as the matched case.  
bconditioned on matching variables. 
cavailable only after April 2001. 
davailable only after April 2000. 
efor ICC and corresponding controls, history of AIDS only if ≥3 months before ICC (see methods).  
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Table 3. Odds Ratios for Cervical Intra-epithelial Neoplasia 2/3 and Invasive Cervical Cancer by cART Use Before and After Adjustment for Nadir 
CD4 Cell Count. The Swiss HIV Cohort Study, 1985-2013. 
History of cART 
use 
Cases  Controls 
ORa 
(95% CI) 
Adjusted ORb 
(95% CI) 
N (%) N (%) 
       
CIN2/3 364  1087    
       
Never 160 (44.0) 513 (47.2) 1 1 
Ever 204 (56.0) 574 (52.8) 1.24 (0.90, 1.70) 0.96 (0.68, 1.35) 
       
   ≤2years    103 (28.3) 231 (21.3) 
1.59 (1.12, 2.26) 1.25 (0.86, 1.81) 
   >2years    101 (27.7) 343 (31.5) 
0.87 (0.59, 1.29) 0.64 (0.42, 0.98) 
  
ICC 
20  60 
   
       
Never 10 (50.0) 32 (53.3) 
1 
1 
Ever 10 (50.0) 28 (46.7) 
1.19 (0.37, 3.82) 
0.62 (0.15, 2.54) 
       
   ≤2years 4 (20.0) 8 (13.3) 
1.60 (0.40, 6.30) 0.97 (0.20, 4.66) 
   >2years 6 (30.0) 20 (33.3) 
0.78 (0.16, 3.86) 0.34 (0.05, 2.26) 
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Abbreviations: cART, combined antiretroviral therapy; CI, confidence interval; CIN, cervical intra-epithelial neoplasia; 
ICC, invasive cervical cancer; OR, odds ratio.  
aconditioned upon matching variables; bconditioned on matching variables and adjusted for nadir CD4 categories in 
Table 2. 
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Table 4. Odds Ratios for Cervical Intra-epithelial Neoplasia 2/3 and Invasive Cervical Cancer by Nadir CD4+ Count, Separately Among never and 
ever cART Users. The Swiss HIV Cohort Study, 1985-2013. 
 Never cART users Ever cART users 
Nadir CD4+ 
cell count, 
cells/µL 
Cases  Controls ORa 
(95% CI) 
Cases   Controls ORa 
(95% CI) 
 N (%) N (%) N % N % 
           
CIN2/3 160  513   204  574   
           
≥350 51 (32.5) 229 (45.1) 1 17 (8.3) 94 (16.4) 1 
200-349 43 (27.4) 126 (24.8) 1.53 (0.96, 2.43) 45 (22.1) 154 (26.8) 1.67 (0.90, 3.01) 
50-199 42 (26.8) 99 (19.5) 1.85 (1.13, 3.05) 93 (45.6) 215 (37.5) 2.51 (1.40, 4.48) 
<50 21 (13.4) 54 (10.6) 1.78 (0.97, 3.26) 49 (24.0) 111 (19.3) 2.58 (1.37, 4.84) 
Unknown 3  5   0  0   
X2 trend (P)     0.013     < 0.001 
Per 100 /µL decrease   1.12 (1.03,1.21)     1.17 (1.05, 1.30) 
      
      
ICC 10  32   10  28   
           
≥350 1 (10.0) 14 (45.2) 
    }    1    
1 (10.0) 2 (7.1) 
   }     1    200-349 4 (40.0) 11 (35.5) 0 (0.0) 4 (14.3) 
50-199 4 (40.0) 5 (16.1) 4.10 (0.60, 28.1) 5 (50.0) 16 (57.1) 2.55 (0.20, 31.8) 
<50 1 (10.0) 1 (3.2) 12.90 (0.38, 436) 4 (40.0) 6 (21.4) 6.41 (0.43, 95.1) 
Unknown 0  1   0  0   
X2 trend (P)   0.004     0.26 
Per 100 /µL decrease   1.65 (1.00, 2.72)     1.05 (0.58, 1.88) 
         
Abbreviations: cART, combined antiretroviral therapy; CI, confidence interval; CIN, cervical intra-epithelial neoplasia; ICC, invasive 
cervical cancer; OR, odds ratio. 
aadjusted for matching variables (see methods).  
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Figure 1. Box plots of CD4+ cell counts at yearly intervals prior to reference date, among cervical intra-
epithelial neoplasia 2/3 and controls, stratified by A) never cART users and B) ever cART users. The Swiss 
HIV Cohort Study, 1985-2013. Abbreviations: CIN2/3 = cervical intra-epithelial grade 2/3; cART = 
combined antiretroviral therapy. Figure 1 A) Never cART users.  
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Figure 1. Box plots of CD4+ cell counts at yearly intervals prior to reference date, among cervical intra-
epithelial neoplasia 2/3 and controls, stratified by A) never cART users and B) ever cART users. The Swiss 
HIV Cohort Study, 1985-2013. Abbreviations: CIN2/3 = cervical intra-epithelial grade 2/3; cART = 
combined antiretroviral therapy. Figure 1 B) Ever cART users.  
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Figure 2. Seropositivity for HPV16 antibodies among cervical intra-epithelial neoplasia 2/3, invasive cervical 
cancer and corresponding controls. The Swiss HIV Cohort Study, 1985-2013.* Significantly different from 
corresponding controls in conditional logistic regression model.Abbreviations: HPV = human papillomavirus; 
CIN2/3 = cervical intra-epithelial grade 2/3; ICC = invasive cervical cancer.  
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